Research Analysts Offer Predictions for CNTX FY2025 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – Lifesci Capital issued their FY2025 EPS estimates for shares of Context Therapeutics in a note issued to investors on Monday, February 23rd. Lifesci Capital analyst C. Zhu expects that the company will earn ($0.36) per share for the year. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Context Therapeutics’ Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.55) EPS.

A number of other equities analysts have also recently commented on CNTX. HC Wainwright lifted their price objective on shares of Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, November 6th. JonesTrading began coverage on shares of Context Therapeutics in a research report on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price for the company. Finally, Wall Street Zen upgraded Context Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 16th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Context Therapeutics Stock Performance

Context Therapeutics stock opened at $2.48 on Wednesday. The stock has a market capitalization of $227.86 million, a P/E ratio of -10.33 and a beta of 1.94. Context Therapeutics has a 52 week low of $0.49 and a 52 week high of $2.85. The stock has a 50-day simple moving average of $1.83 and a 200 day simple moving average of $1.32.

Hedge Funds Weigh In On Context Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Clear Harbor Asset Management LLC raised its holdings in shares of Context Therapeutics by 60.5% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after acquiring an additional 35,000 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Context Therapeutics in the third quarter valued at approximately $100,000. Blue Owl Capital Holdings LP raised its stake in Context Therapeutics by 0.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after purchasing an additional 188,202 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.